EP2685825A4 - Substituierte imadazopyrimidin-5(6h)-one als allosterische modulatoren von mglur5-rezeptoren - Google Patents

Substituierte imadazopyrimidin-5(6h)-one als allosterische modulatoren von mglur5-rezeptoren

Info

Publication number
EP2685825A4
EP2685825A4 EP12757940.7A EP12757940A EP2685825A4 EP 2685825 A4 EP2685825 A4 EP 2685825A4 EP 12757940 A EP12757940 A EP 12757940A EP 2685825 A4 EP2685825 A4 EP 2685825A4
Authority
EP
European Patent Office
Prior art keywords
imadazopyrimidin
ones
substituted
allosteric modulators
mglur5 receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12757940.7A
Other languages
English (en)
French (fr)
Other versions
EP2685825A1 (de
Inventor
P Jeffrey Conn
Craig W Linsley
Shaun R Stauffer
Jose Manuel Bartolome-Nebreda
Gregor James Macdonald
Susana Conde-Ceide
Carrie K Jones
Maria Luz Martin-Martin
Han Min Tong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP2685825A1 publication Critical patent/EP2685825A1/de
Publication of EP2685825A4 publication Critical patent/EP2685825A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP12757940.7A 2011-03-15 2012-03-14 Substituierte imadazopyrimidin-5(6h)-one als allosterische modulatoren von mglur5-rezeptoren Withdrawn EP2685825A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452921P 2011-03-15 2011-03-15
PCT/US2012/029085 WO2012125732A1 (en) 2011-03-15 2012-03-14 Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors

Publications (2)

Publication Number Publication Date
EP2685825A1 EP2685825A1 (de) 2014-01-22
EP2685825A4 true EP2685825A4 (de) 2014-09-10

Family

ID=46831091

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12757940.7A Withdrawn EP2685825A4 (de) 2011-03-15 2012-03-14 Substituierte imadazopyrimidin-5(6h)-one als allosterische modulatoren von mglur5-rezeptoren

Country Status (5)

Country Link
EP (1) EP2685825A4 (de)
JP (1) JP2014508172A (de)
AU (1) AU2012229983A1 (de)
CA (1) CA2830220A1 (de)
WO (1) WO2012125732A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2820262A1 (en) 2010-12-08 2012-06-14 Vanderbilt University Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
US8865725B2 (en) * 2011-03-15 2014-10-21 Vanderbilt University Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors
WO2013192306A1 (en) * 2012-06-21 2013-12-27 Bristol-Myers Squibb Company Positive allosteric modulators of mglur2
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
BR112022007491A2 (pt) * 2019-10-21 2022-07-12 Sk Biopharmaceuticals Co Ltd Medicamento, composição farmacêutica e método para prevenção, alívio ou tratamento de distúrbio cognitivo, e, uso de um composto de imidazopirimidina ou imidazotriazina
WO2023064223A1 (en) 2021-10-11 2023-04-20 Gossamer Bio Services, Inc. Tri-substituted pyridines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2008107418A1 (en) * 2007-03-05 2008-09-12 Novartis Ag Fused pyrimidinone compounds as mglur ligands
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334210D0 (en) * 1983-12-22 1984-02-01 Roussel Lab Ltd Imidazo(1 2-c)pyrimidines
JPH01203366A (ja) * 1988-02-10 1989-08-16 Mitsui Petrochem Ind Ltd Ｎ−置換イミダゾール誘導体
AU2007280428B2 (en) * 2006-08-04 2012-04-12 Merz Pharma Gmbh & Co. Kgaa Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
US8034806B2 (en) * 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2008107418A1 (en) * 2007-03-05 2008-09-12 Novartis Ag Fused pyrimidinone compounds as mglur ligands
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012125732A1 *

Also Published As

Publication number Publication date
EP2685825A1 (de) 2014-01-22
JP2014508172A (ja) 2014-04-03
CA2830220A1 (en) 2012-09-20
WO2012125732A8 (en) 2013-10-17
WO2012125732A1 (en) 2012-09-20
AU2012229983A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
HRP20190128T1 (hr) Novi spojevi kao modulatori protein kinaza
AP2014007615A0 (en) Solid forms of nematocical sulfonamides
EP2863922A4 (de) Substituierte bicyclische alkoxypyrazolanaloga als allosterische modulatoren von mglur5-rezeptoren
EP2680848A4 (de) Stabile zusammensetzungen aus tetrahydrobiopterin
EP2709609A4 (de) Heterozyklische verbindungen
HK1195298A1 (zh) 作為 變構調節劑的乙炔基衍生物
EP2648723A4 (de) Bicyclische pyrazolverbindungen als allosterische mglur5-rezeptormodulatoren
ZA201306586B (en) Thynyl derivatives as positive allosteric modulators of the mglur5
EP2863912A4 (de) Substituierte bicyclische alkoxypyrazolanaloga als allosterische modulatoren von mglur5-rezeptoren
GB201120644D0 (en) Herbicidal uses of compounds
EP2685825A4 (de) Substituierte imadazopyrimidin-5(6h)-one als allosterische modulatoren von mglur5-rezeptoren
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
EP2776411A4 (de) Modulatoren von c3a-rezeptoren
PL2766008T3 (pl) Kompozycja do podawania donosowego o ulepszonej stabilności
EP2766829A4 (de) Proaktive bereitstellung von assoziierten aufgaben für identifizierte einheiten
ZA201402165B (en) Compositions of lopinavir
ZA201402166B (en) Compositions of efavirenz
CR20130603A (es) Compuestos novedosos como inhibidores de diacilglicerol
EP2680843A4 (de) Derivate von pyrazolsubstituierten amino-heteroaryl-verbindungen
EP2768481A4 (de) Zusammensetzungen zur verringerung von nebenwirkungen
EP2684869A4 (de) Herstellung von 3-mercaptopropionaten
EP2804607A4 (de) Synthese von raltegravir
EP2785723A4 (de) Difluormethylierung von ungesättigten verbindungen
BR112013014710A2 (pt) entrega de compostos funcionais
EP2702991A4 (de) Zusammensetzung von entacopon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20140811

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101AFI20140805BHEP

Ipc: A61P 25/00 20060101ALI20140805BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150310